Other Specified Personality Disorder
Conditions
Interventions
Sponsors
Universiteit van Amsterdam and PsyQ Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: - Patients with Other Specified PD based on the DSM-5 as primary diagnosis (assessed with SCID-5-P). - Age 18-70 - Ability to understand, read, write and speak Dutch.
Exclusion criteria
Exclusion criteria: - DSM-5 alcohol or drug dependence. (After 3 months of abstinence participation is possible). - Comorbid psychotic disorder - DSM-5 Bipolar disorder, type 1 (current or past) - (Sub)threshold Borderline PD - Acute suicide risk - IQ<80 - Schema Therapy of any kind (e.g., individual, group, inpatient, outpatient, day treatment) in the past year. - patients should not start with any form of psychological treatment or medication during screening or during the study’s treatment or waitlist period. Medication should be on a stable level for 3 months, if not stopped. (Non-PD focused supportive treatment may be continued during wait and screening, but not during the study treatment and study 1-year follow-up period) - Not able to plan (group) therapy sessions of 90 minutes within the treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome variable is change in severity of manifestations of OSPD, measured with ADP-IV (Schotte & De Donker, 1996) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. PD-related beliefs will be assessed with the PDBQ-69 (Arntz et al., 2004). Beliefs related to the six most common PDs are represented in this instrument. The participants will probably most frequently have PD-traits of these six PDs (avoidant, dependent, obsessive-compulsive, paranoid, histrionic, and borderline PD). 2. Self-esteem will be assessed with the 10-item version of Rosenberg’s Self-Esteem Scale (RSES; Rosenberg, 1965; Franck et al., 2008). 3. Self-Ideal Discrepancy will be assessed by calculating the difference between the Self and Goal scales of the Miskimins Self-Goal-Other Discrepancy Scale (MSGO; Miskimins et al., 1971). 4. General, social and societal functioning will be assessed with the WHODAS, taken by the research assistant (Üstün, 2010). 5. Happiness will be assessed with the 1-item happiness question validated in more than 30 countries (Veenhoven, 2011). 6. Quality of Life will be assessed with the EuroQol EQ-5D-5L (Herdman et al., 2011; Rabin & Charro, 2001). 7. Schema Modes will be assessed with the Schema Mode Inventory-2 (SMI-2; Bamelis et al., 2011), which assesses the frequency of Schema Mode activation for the modes most relevant for the pertinent PDs. 8. Early Maladaptive Schemas will be assessed with the YSQ-Revised, a shortened version of the YSQ (YSQ-R; Rijkeboer, 2013). 9. General psychopathological symptoms as an index of severity of syndromal disorders will be assessed with the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983). 10. Medication and mental health care use will be monitored at each assessment. 11. New variables will be composed to measure mistrust, avoidance and lack of selfdiscipline. | — |
Contacts
Public ContactProf. dr. A. Arntz Arntz
Universiteit van Amsterdam
Outcome results
None listed